quinazolines has been researched along with Dermatoses in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (44.44) | 29.6817 |
| 2010's | 14 (38.89) | 24.3611 |
| 2020's | 3 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Fu, H; Gao, Z; He, Q; Jin, Y; Luo, P; Pan, Z; Shen, X; Xu, Z; Yan, H; Yang, B | 1 |
| Du, W; Huang, F; Li, M; Lin, Y; Qu, L; Rao, G; Sun, Y; Tong, X; Zhang, Y; Zhu, D | 1 |
| Akagunduz, B; Çoban, A; Guven, DC; Kara, AV; Mammadov, R; Ozcicek, F; Suleyman, B; Suleyman, H; Yazici, GN | 1 |
| Chen, M; Li, Y; Tang, F; Tong, M; Wen, H; Xiao, R; Zhang, G; Zhao, M | 1 |
| du Bois, A; Elser, G; Harter, P; Hilpert, F; Kimmig, R; Kurzeder, C; Rau, J; Sehouli, J | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Arrieta, O; Bacon-Fonseca, L; de la Garza-Salazar, J; Flores-Estrada, D; López-Macías, D; Macedo-Pérez, EO; Martínez-Hernández, JN; Ramírez-Tirado, LA; Vega-González, MT | 1 |
| Burlando, M; Cattaneo, D; Cozzani, E; Gugliotta, L; Iurlo, A; Merlo, G; Parodi, A; Pierri, I | 1 |
| Blackwell, KL; Byrne, JA; Di Leo, A; Gomez, HL; Koch, KM; Koehler, M; Laabs, SM; Lacouture, ME; Preston, AJ; Salazar, VM; Sweetman, RW | 1 |
| Hattori, K; Igarashi, S; Ishikawa, N; Kawano, N; Masuda, N; Matsumoto, Y; Miyazaki, T; Ogino, S; Ohta, M; Orita, M; Takeuchi, M; Yokoyama, K | 1 |
| Awada, A; Bachelot, T; Blackwell, K; DeSilvio, M; Johnston, S; Kaufman, B; Salazar, V; Spector, N; Trudeau, M; Westlund, R; Zaks, T | 1 |
| Schwartz, J | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Frankel, C; Palmieri, FM | 1 |
| Chang, KW; Lin, MH; Lin, SC; Miner, JH | 1 |
| Awada, A; Azim, HA; Metzger Filho, O; Saini, KS | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Honma, M; Suzuki, H; Yamamoto, N | 1 |
| Suzuki, Y; Yamamoto, T | 1 |
| Guo, Z; Li, J | 1 |
| Awada, AH; Besse-Hammer, T; Dumez, H; Fleischer, F; Hendlisz, A; Piccart, M; Schöffski, P; Stopfer, P; Uttenreuther-Fischer, M; Wolter, P | 1 |
| Chang, H; Cho, BC; Cho, J; Ha, SJ; Hong, YK; Jeong, JH; Kim, HR; Kim, JH; Kim, SH; Kim, SM; Shim, HS; Sung, JH; Tania, C | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Bona, C; Kodera, T; McGaha, T; Phelps, R; Pines, M; Spiera, H | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E | 1 |
| Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
| Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Gross, GE; Schäd, SG; Zoller, A | 1 |
| Kano, Y | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Bona, C; McGaha, TL; Phelps, RG; Spiera, H | 1 |
| Allegra, CJ; Curt, GA; James, WD; Major, WB; Porter, MB; Weiss, RB | 1 |
| Johansson, EA; Niemi, KM; Ranki, A | 1 |
| Alison, DL; Calvert, AH; Harland, SJ; Jackman, AL; Jones, TR; McElwain, TJ; Newell, DR; Robinson, BA; Siddik, ZH; Wiltshaw, E | 1 |
7 review(s) available for quinazolines and Dermatoses
| Article | Year |
|---|---|
Essential Thrombocythemia: The Dermatologic Point of View.
Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Quinazolines; Skin Diseases; Thrombocythemia, Essential | 2015 |
Analysis of dermatologic events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Exanthema; Female; Fluorouracil; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Paclitaxel; Quinazolines; Skin Diseases; Treatment Outcome | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Breast Neoplasms; Capecitabine; Cytotoxins; Deoxycytidine; Diarrhea; Drug Delivery Systems; Epothilones; Female; Fluorouracil; Humans; Lapatinib; Quinazolines; Signal Transduction; Skin Diseases; Trastuzumab | 2009 |
Lapatinib side-effect management.
Topics: Antineoplastic Agents; Diarrhea; Humans; Lapatinib; Paronychia; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2010 |
Prevention and management of major side effects of targeted agents in breast cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast; Breast Neoplasms; Cardiovascular Diseases; Female; Gastrointestinal Diseases; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Skin Diseases; Trastuzumab | 2012 |
[Adverse drug reactions induced by molecular target therapy].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cetuximab; Communicable Diseases; ErbB Receptors; Etanercept; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Lung Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Tumor Necrosis Factor; Skin Diseases; Tumor Necrosis Factor-alpha | 2007 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
9 trial(s) available for quinazolines and Dermatoses
| Article | Year |
|---|---|
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Polyethylene Glycols; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2013 |
Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pre-Exposure Prophylaxis; Quinazolines; Risk Factors; Skin Diseases; Tetracycline | 2015 |
Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Recurrence; Skin Diseases; Treatment Outcome | 2009 |
Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Female; Gastrointestinal Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Skin Diseases; Taxoids | 2013 |
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Skin Diseases; Treatment Outcome | 2013 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome | 2005 |
20 other study(ies) available for quinazolines and Dermatoses
| Article | Year |
|---|---|
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Diarylheptanoids; Disease Models, Animal; DNA Damage; HaCaT Cells; Humans; Keratinocytes; Membrane Potential, Mitochondrial; Mice, Inbred C57BL; Mitochondria; Piperidines; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Skin; Skin Diseases | 2021 |
Vasicine alleviates 2,4-dinitrochlorobenzene-induced atopic dermatitis and passive cutaneous anaphylaxis in BALB/c mice.
Topics: Alkaloids; Animals; Anti-Allergic Agents; Cytokines; Dermatitis, Atopic; Dinitrochlorobenzene; Immunoglobulin E; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Quinazolines; Skin; Skin Diseases | 2022 |
Effects of adenosine triphosphate on vandetanib induced skin damage in rats.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Glutathione; Male; Malondialdehyde; Piperidines; Protein Kinase Inhibitors; Quinazolines; Rats, Wistar; Skin; Skin Diseases | 2020 |
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Indole Alkaloids; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Quinazolines; Signal Transduction; Skin; Skin Diseases; Th17 Cells; Toll-Like Receptor 7 | 2019 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
Potent CCR4 antagonists: synthesis, evaluation, and docking study of 2,4-diaminoquinazolines.
Topics: Animals; Binding Sites; Cell Line; Computer Simulation; Drug Evaluation, Preclinical; Humans; Injections, Subcutaneous; Mice; Models, Chemical; Models, Molecular; Molecular Structure; Oxazolone; Quinazolines; Receptors, CCR4; Skin Diseases; Stereoisomerism; Structure-Activity Relationship | 2008 |
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids | 2009 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
Epidermal hyperproliferation in mice lacking fatty acid transport protein 4 (FATP4) involves ectopic EGF receptor and STAT3 signaling.
Topics: Animals; Epidermal Growth Factor; Epidermis; Epiregulin; ErbB Receptors; Fatty Acid Transport Proteins; Keratinocytes; Mice; Mice, Mutant Strains; Mice, Transgenic; Mutation; Phenotype; Quinazolines; Signal Transduction; Skin; Skin Diseases; STAT3 Transcription Factor; Tyrphostins | 2010 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders.
Topics: Base Sequence; Cell Line; Chromatography, Liquid; Erlotinib Hydrochloride; Humans; Jurkat Cells; Lymphocytes; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; RNA, Small Interfering; Skin Diseases; Tandem Mass Spectrometry | 2011 |
Reactive perforating collagenosis during erlotinib therapy.
Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Effect of halofuginone on the development of tight skin (TSK) syndrome.
Topics: Animals; Animals, Newborn; Collagen; Disease Models, Animal; Fibrosis; Humans; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Piperidines; Protein Synthesis Inhibitors; Quinazolines; Quinazolinones; Scleroderma, Systemic; Skin Diseases | 2002 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
Erlotinib-associated skin reactions - case report and proposal for classification.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2006 |
Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
Topics: Animals; Cells, Cultured; Collagen; Collagen Type I; DNA-Binding Proteins; Fibroblasts; Gene Expression; Hyperplasia; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Mutant Strains; Piperidines; Quinazolines; Quinazolinones; Receptors, Transforming Growth Factor beta; Sclerosis; Signal Transduction; Skin; Skin Diseases; Smad3 Protein; Trans-Activators; Transforming Growth Factor beta | 2002 |
Skin reactions induced by trimetrexate, an analog of methotrexate.
Topics: Cellulitis; Dermatitis, Exfoliative; Humans; Quinazolines; Skin Diseases; Trimetrexate | 1986 |
Modification of lymphocyte subsets in Jessner's lymphocytic infiltration of the skin during proquazone treatment.
Topics: Adult; Antibodies, Monoclonal; Cell Movement; Female; Humans; Immunohistochemistry; Lymphocytes; Male; Middle Aged; Quinazolines; Recurrence; Skin Diseases | 1988 |
A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Topics: Acetylglucosaminidase; Acid Phosphatase; Alanine Transaminase; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Folic Acid; Folic Acid Antagonists; Glomerular Filtration Rate; Hematologic Diseases; Hyperbilirubinemia; Kidney Diseases; Leucyl Aminopeptidase; Neoplasms; Quinazolines; Skin Diseases; Thymidylate Synthase | 1986 |